Fractyl Health (GUTS) Amortization of Deferred Charges (2023 - 2026)
Fractyl Health's (GUTS) quarterly Amortization of Deferred Charges came in at $65000.0 in Q1 2026, down 17.72% YoY from $79000.0 in Q1 2025, and down 5.8% on a QoQ basis from $69000.0 in Q4 2025.
Fractyl Health (GUTS) Amortization of Deferred Charges (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Amortization of Deferred Charges data on file, last reported at $65000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges fell 17.72% year-over-year to $65000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $282000.0 (down 35.02% YoY) and the FY2025 annual result came in at $296000.0, down 17.09% from the prior year.
- Amortization of Deferred Charges eased to $65000.0 in Q1 2026, from $69000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $237000.0 in Q3 2024 to a low of $2000.0 in Q1 2024.
- A 4-year average of $75200.0 and a median of $70500.0 in 2025 frame the typical range for Amortization of Deferred Charges.
- The widest YoY moves for Amortization of Deferred Charges: up 3850.0% in 2025, down 69.62% in 2025.
- Tracing GUTS's Amortization of Deferred Charges over 4 years: stood at $34000.0 in 2023, then jumped by 141.18% to $82000.0 in 2024, then fell by 15.85% to $69000.0 in 2025, then fell by 5.8% to $65000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $65000.0 (Q1 2026), $69000.0 (Q4 2025), and $72000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Fractyl Health | 123.81 Mn | 123.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62,000.00 |
| Jun 30, 2026 | 62,000.00 |
| Mar 31, 2026 | 65,000.00 |
| Mar 31, 2026 | 65,000.00 |
| Dec 31, 2025 | 69,000.00 |
| Dec 31, 2025 | 69,000.00 |
| Sep 30, 2025 | 72,000.00 |
| Sep 30, 2025 | 72,000.00 |
| Jun 30, 2025 | 76,000.00 |
| Jun 30, 2025 | 76,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Dec 31, 2024 | 82,000.00 |
| Dec 31, 2024 | 82,000.00 |
| Sep 30, 2024 | 237,000.00 |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 36,000.00 |
| Jun 30, 2024 | 36,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |